Compare HG & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HG | FOLD |
|---|---|---|
| Founded | 2013 | 2002 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.1B |
| IPO Year | 2023 | 2007 |
| Metric | HG | FOLD |
|---|---|---|
| Price | $28.14 | $14.26 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 8 |
| Target Price | $29.00 | ★ $29.43 |
| AVG Volume (30 Days) | 434.6K | ★ 16.3M |
| Earning Date | 11-04-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.19 | N/A |
| Revenue | ★ $2,745,461,000.00 | $598,704,000.00 |
| Revenue This Year | $25.41 | $21.49 |
| Revenue Next Year | $0.82 | $18.42 |
| P/E Ratio | $6.77 | ★ N/A |
| Revenue Growth | 21.12 | ★ 21.28 |
| 52 Week Low | $16.80 | $5.51 |
| 52 Week High | $28.72 | $14.36 |
| Indicator | HG | FOLD |
|---|---|---|
| Relative Strength Index (RSI) | 60.58 | 91.24 |
| Support Level | $27.45 | $10.64 |
| Resistance Level | $28.72 | $14.36 |
| Average True Range (ATR) | 0.53 | 0.29 |
| MACD | -0.00 | 0.41 |
| Stochastic Oscillator | 73.35 | 97.84 |
Hamilton Insurance Group Ltd is a specialty insurance and reinsurance company. It operates globally, with underwriting operations in London, Dublin, Bermuda, and the United States. It operates three principal underwriting platforms (Hamilton Global Specialty, Hamilton Select and Hamilton Re) that are categorized into two reporting business segments: International and Bermuda.
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.